OTCMKTS:BIOVF Swedish Orphan Biovitrum (BIOVF) Stock Price, News & Analysis $45.72 -0.29 (-0.62%) As of 03:56 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartEarningsNews and TrendsShort Interest About Swedish Orphan Biovitrum Stock (OTCMKTS:BIOVF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get BIOVF alerts:Sign Up Key Stats Today's Range$45.72▼$45.7250-Day Range$42.80▼$48.2152-Week Range$34.88▼$49.03Volume110 shsAverage Volume1,488 shsMarket Capitalization$16.27 billionP/E Ratio101.59Dividend YieldN/APrice TargetN/AConsensus RatingModerate Buy Company Overview Swedish Orphan Biovitrum AB, commonly known as Sobi, is a Sweden-based biopharmaceutical company focused on developing, manufacturing and commercializing medicines for rare diseases. Its principal therapeutic areas include hematology, immunology and specialty care, with an emphasis on conditions that often have limited treatment options. Sobi’s portfolio includes therapies for rare blood disorders, immune-mediated diseases and other specialized conditions. Its products include Doptelet (avatrombopag), Gamifant (emapalumab), Aspaveli (pegcetacoplan), Alprolix (eftrenonacog alfa) and Elocta (efmoroctocog alfa), along with additional medicines marketed through collaboration and licensing arrangements. The company also conducts research and development to expand its pipeline of treatments for rare diseases. Headquartered in Stockholm, Sobi serves patients and healthcare providers internationally through its own commercial operations and strategic partnerships. The company traces its roots to Swedish pharmaceutical businesses and adopted the Swedish Orphan Biovitrum name following the combination of Swedish Orphan and Biovitrum in 2010. Its products are marketed across Europe, North America and other international markets, depending on the therapy and regional approvals.AI Generated. May Contain Errors. Read More Swedish Orphan Biovitrum Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks41st Percentile Overall ScoreBIOVF MarketRank™: 2.04449152542 of 5 starsSwedish Orphan Biovitrum scored higher than 41% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.5 / 5Analyst RatingModerate Buy Consensus RatingSwedish Orphan Biovitrum has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 4 buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageSwedish Orphan Biovitrum has only been the subject of 1 research reports in the past 90 days.Read more about Swedish Orphan Biovitrum's stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth73.30% Earnings GrowthEarnings for Swedish Orphan Biovitrum are expected to grow by 73.30% in the coming year, from $1.91 to $3.31 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Swedish Orphan Biovitrum is 101.59, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 38.76.Price to Earnings Ratio vs. SectorThe P/E ratio of Swedish Orphan Biovitrum is 101.59, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.98.Price to Book Value per Share RatioSwedish Orphan Biovitrum has a P/B Ratio of 4.22. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Swedish Orphan Biovitrum's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.09% of the float of Swedish Orphan Biovitrum has been sold short.Short Interest Ratio / Days to CoverSwedish Orphan Biovitrum has a short interest ratio ("days to cover") of 999.99, which indicates bearish sentiment.Change versus previous monthShort interest in Swedish Orphan Biovitrum has recently decreased by 5.91%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSwedish Orphan Biovitrum does not currently pay a dividend.Dividend GrowthSwedish Orphan Biovitrum does not have a long track record of dividend growth. News and Social Media2.1 / 5News Sentiment0.42 News SentimentSwedish Orphan Biovitrum has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Swedish Orphan Biovitrum this week, compared to 1 article on an average week. Company OwnershipN/AInsider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Swedish Orphan Biovitrum insiders have not sold or bought any company stock.Percentage Held by InstitutionsSwedish Orphan Biovitrum has minimal institutional ownership at this time.Read more about Swedish Orphan Biovitrum's insider trading history. Receive BIOVF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Swedish Orphan Biovitrum and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BIOVF Stock News HeadlinesHarry Gillis Raises Swedish Orphan Biovitrum Price Target to SEK570, Reiterates Buy on Tryngolza-Led Growth UpsideOctober 20 at 4:50 AM | tipranks.comSwedish Orphan Biovitrum (BIOVF) Projected to Announce Quarterly Earnings on TuesdayOctober 20 at 3:57 AM | americanbankingnews.comMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up Amazon and Netflix under $3 per share in 2005. Now the chief investment strategist at The Oxford Club has identified three AI stocks he believes could be the most profitable investments of the next decade.October 23 at 1:00 AM | The Oxford Club (Ad)Sobi Completes Class C Share Issue to Fund Employee Incentive ProgrammeAugust 31, 2026 | tipranks.comSobi partners with Innate Pharma in $580m lacutamab deal to expand rare cancer portfolioAugust 10, 2026 | tipranks.comMitchell Kapoor Reiterates Buy on Swedish Orphan Biovitrum, Maintains SEK575 12-Month Price Target Amid Solid Late-Stage Pipeline and CEO TransitionAugust 3, 2026 | tipranks.comSobi lifts 2026 outlook as Q2 revenue surges and gout pipeline advancesJuly 16, 2026 | tipranks.comCanada’s Drug Agency Issues Positive Reimbursement Recommendation for EMPAVELI® (pegcetacoplan) for the Treatment of C3G and Primary IC-MPGNJuly 9, 2026 | financialpost.comFSee More Headlines BIOVF Stock Analysis - Frequently Asked Questions How have BIOVF shares performed this year? Swedish Orphan Biovitrum's stock was trading at $35.25 at the beginning of 2026. Since then, BIOVF stock has increased by 29.7% and is now trading at $45.7150. How were Swedish Orphan Biovitrum's earnings last quarter? Swedish Orphan Biovitrum (OTCMKTS:BIOVF) issued its quarterly earnings data on Tuesday, April, 28th. The company reported $0.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.38 by $0.07. The company had revenue of $755.76 million for the quarter, compared to the consensus estimate of $749.76 million. Swedish Orphan Biovitrum had a trailing twelve-month return on equity of 17.72% and a net margin of 4.74%. How do I buy shares of Swedish Orphan Biovitrum? Shares of BIOVF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Swedish Orphan Biovitrum own? Based on aggregate information from My MarketBeat watchlists, some other companies that Swedish Orphan Biovitrum investors own include Millicom International Cellular (TIGO), Novo Nordisk A/S (NVO), Oscar Health (OSCR), Cynata Therapeutics (CYYNF), Semafo (SMF), EnQuest (ENQ) and Marks and Spencer Group (MKS). Company Calendar Last Earnings4/28/2026Today10/23/2026Next Earnings (Estimated)10/27/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolOTCMKTS:BIOVF CIKN/A Webwww.sobi.com Phone(468) 697-2000FaxN/AEmployees1,900Year Founded2010Profitability EPS (Trailing Twelve Months)$0.45 Trailing P/E Ratio101.59 Forward P/E Ratio23.93 P/E GrowthN/ANet Income$48.85 million Net Margins4.74% Pretax Margin4.68% Return on Equity17.72% Return on Assets9.27% Debt Debt-to-Equity Ratio0.20 Current Ratio0.88 Quick Ratio0.55 Sales & Book Value Annual Sales$2.89 billion Price / Sales5.64 Cash Flow$4.54 per share Price / Cash Flow10.06 Book Value$10.83 per share Price / Book4.22Miscellaneous Outstanding Shares356,000,000Free FloatN/AMarket Cap$16.27 billion OptionableNot Optionable Beta0.47 Social Links The 7 Best High-Yield Dividend Stocks for 2027Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.Get This Free Report This page (OTCMKTS:BIOVF) was last updated on 10/23/2026 by MarketBeat.com Staff. From Our PartnersTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billi...Banyan Hill Publishing | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Swedish Orphan Biovitrum Please log in to your account or sign up in order to add this asset to your watchlist. Share Swedish Orphan Biovitrum With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
